文献速递前列腺癌

活检Gleason 7分降级至前列腺切除Gleason 6分对生化复发与前列腺癌特异性死亡率的影响

The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
PubMed 文献 · J Urol · 2016-11-12

研究纳入1984至2014年在本机构接受根治性前列腺切除术的10,236例活检与切除Gleason评分均为6或7分且无升级的患者,分为三组:活检与切除均为6分(6,923例,67.6%)、活检7分降级至切除6分(648例,6.3%)、活检与切除均为7分(2,665例,26.0%)。中位随访5年(范围1至29年),降级组生化复发风险独立高于双6分组(校正HR 1.87,p<0.0001),但前列腺癌特异性死亡率无独立关联(校正HR 1.65,p=0.636)。

要点

  • 活检Gleason 7分降级至切除Gleason 6分是生化复发的独立预测因素(校正HR 1.87,p<0.0001)。
  • 降级与前列腺癌特异性死亡率无独立关联(校正HR 1.65,p=0.636)。
  • 降级组生化复发风险介于双6分组与双7分组之间,双6分组最低,双7分组最高(均p<0.001)。

核心结论

  • 活检Gleason 7分降级至根治性前列腺切除Gleason 6分是生化复发的独立预测因素,但与前列腺癌特异性死亡率无独立关联,可能归因于存在少量Gleason 4模式。

研究设计与样本

  • 回顾性队列研究,纳入1984至2014年在本机构接受根治性前列腺切除术的23,918例男性中的10,236例活检与切除Gleason评分均为6或7分且无升级者。
  • 队列分为三组:组1活检与切除均为Gleason 6分(6,923例,67.6%);组2活检Gleason 7分降级至切除Gleason 6分(648例,6.3%);组3活检与切除均为Gleason 7分(2,665例,26.0%)。
  • 采用Cox回归和竞争风险分析校正临床病理变量后比较生化复发与前列腺癌特异性死亡风险。
  • 中位随访5年(范围1至29年)。

主要发现

  • 随访期间992例发生生化复发,95例死于前列腺癌。
  • 降级组(组2)生化复发无生存优于组3(活检与切除均为Gleason 7分)(p<0.001),但劣于组1(活检与切除均为Gleason 6分)(p<0.001)。
  • 降级与生化复发独立相关(校正HR 1.87,p<0.0001)。
  • 降级与前列腺癌特异性死亡率无独立关联(校正HR 1.65,p=0.636)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gleason score is one of the most important prognostic indicators for prostate cancer. Downgrading from biopsy Gleason score 7 to radical prostatectomy Gleason score 6 occurs commonly and yet to our knowledge the impact on survival outcomes is unknown. We examined biochemical recurrence and prostate cancer specific mortality risk in a large cohort evaluated by a single group of expert urological pathologists. MATERIALS AND METHODS: Of 23,918 men who underwent radical prostatectomy at our institution between 1984 and 2014, 10,236 with biopsy and radical prostatectomy Gleason score 6 or 7 without upgrading were included in analysis. The cohort was divided into 3 groups, including group 1-biopsy and radical prostatectomy Gleason score 6 in 6,923 patients (67.6%), group 2-Gleason score 7 downgraded to radical prostatectomy Gleason score 6 in 648 (6.3%) and group 3-biopsy and radical prostatectomy Gleason score 7 in 2,665 (26.0%). Biochemical recurrence and prostate cancer specific mortality risks were compared using Cox regression and competing risk analyses adjusting for clinicopathological variables. RESULTS: At a median followup of 5 years (range 1 to 29), 992 men experienced biochemical recurrence and 95 had died of prostate cancer. Biochemical recurrence-free survival in downgraded cases (group 2) was better than in group 3 cases, which had Gleason score 7 on biopsy and radical prostatectomy (p <0.001), but worse than group 1 cases, which had Gleason score 6 on biopsy and radical prostatectomy (p <0.001). Downgrading was independently associated with biochemical recurrence (adjusted HR 1.87, p <0.0001) but not with prostate cancer specific mortality (adjusted HR 1.65, p = 0.636). CONCLUSIONS: Downgrading from biopsy Gleason score 7 to radical prostatectomy Gleason score 6 was an independent predictor of biochemical recurrence but not prostate cancer specific mortality, likely due to the presence of minor amounts of Gleason pattern 4.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ham WS, Chalfin HJ, Feng Z, et al. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. J Urol. 2016. PMID: 27847296. doi:10.1016/j.juro.2016.11.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。